{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:30:30Z","timestamp":1792099830421,"version":"4.4.0"},"publisher-location":"Cham","reference-count":133,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030203009","type":"print"},{"value":"9783030203016","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-20301-6_7","type":"book-chapter","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T12:03:54Z","timestamp":1566907434000},"page":"105-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Bone Metastasis of Breast Cancer"],"prefix":"10.1007","author":[{"given":"Rie K.","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takae M.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Theriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"issue":"20","key":"7_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20):6243s\u20136249s","journal-title":"Clin Cancer Res"},{"issue":"7494","key":"7_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/bmj.330.7494.769","volume":"330","author":"MC Gainford","year":"2005","unstructured":"Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769\u2013773","journal-title":"BMJ"},{"issue":"12","key":"7_CR3","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O","volume":"58","author":"V Scheid","year":"1986","unstructured":"Scheid V, Buzdar AU, Smith TL, Hortobagyi GN (1986) Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58(12):2589\u20132593","journal-title":"Cancer"},{"issue":"4","key":"7_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","volume":"36","author":"TA Plunkett","year":"2000","unstructured":"Plunkett TA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 36(4):476\u2013482","journal-title":"Eur J Cancer"},{"issue":"2","key":"7_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","volume":"89","author":"SM Domchek","year":"2000","unstructured":"Domchek SM, Younger J, Finkelstein DM, Seiden MV (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89(2):363\u2013368","journal-title":"Cancer"},{"issue":"1","key":"7_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","volume":"131","author":"N Sathiakumar","year":"2012","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Brill I, Kilgore ML (2012) Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999\u20132006. Breast Cancer Res Treat 131(1):231\u2013238","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.bjc.6601198","volume":"89","author":"JJ James","year":"2003","unstructured":"James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JFR (2003) Bone metastases from breast carcinoma: histopathological\u00a0\u2013 radiological correlations and prognostic features. Br J Cancer 89(4):660\u2013665","journal-title":"Br J Cancer"},{"issue":"23","key":"7_CR8","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.2000.18.23.3925","volume":"18","author":"M Colleoni","year":"2000","unstructured":"Colleoni M, O\u2019Neill A, Goldhirsch A, Gelber RD, Bonetti M, Th\u00fcrlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam C-M (2000) Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18(23):3925\u20133935","journal-title":"J Clin Oncol"},{"issue":"7","key":"7_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/bjc.2015.308","volume":"113","author":"Y Delpech","year":"2015","unstructured":"Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK (2015) Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer 113(7):1003\u20131009","journal-title":"Br J Cancer"},{"issue":"1","key":"7_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S8756-3282(01)00642-1","volume":"30","author":"AM Parfitt","year":"2002","unstructured":"Parfitt AM (2002) Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30(1):5\u20137","journal-title":"Bone"},{"issue":"3","key":"7_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.1547","volume":"27","author":"J Xiong","year":"2012","unstructured":"Xiong J, O\u2019Brien CA (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 27(3):499\u2013505","journal-title":"J Bone Miner Res"},{"issue":"17","key":"7_CR12","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1128\/MCB.00356-06","volume":"26","author":"Q Fu","year":"2006","unstructured":"Fu Q, Manolagas SC, O\u2019Brien CA (2006) Parathyroid hormone controls receptor activator of NF- B ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26(17):6453\u20136468","journal-title":"Mol Cell Biol"},{"issue":"6","key":"7_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","volume":"5","author":"S Tatsumi","year":"2007","unstructured":"Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5(6):464\u2013475","journal-title":"Cell Metab"},{"issue":"1","key":"7_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/toxsci\/55.1.171","volume":"55","author":"EJ O\u2019Flaherty","year":"2000","unstructured":"O\u2019Flaherty EJ (2000) Modeling normal aging bone loss, with consideration of bone loss in osteoporosis. Toxicol Sci 55(1):171\u2013188","journal-title":"Toxicol Sci"},{"issue":"7","key":"7_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/cncr.21335","volume":"104","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, LeBoff MS, Bassford TL (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104(7):1520\u20131530","journal-title":"Cancer"},{"issue":"3","key":"7_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/cncr.21201","volume":"104","author":"C Poznak Van","year":"2005","unstructured":"Van Poznak C, Sauter NP (2005) Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 104(3):443\u2013456","journal-title":"Cancer"},{"issue":"4","key":"7_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1349-7006.2011.02195.x","volume":"103","author":"L Mathot","year":"2012","unstructured":"Mathot L, Stenninger J (2012) Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 103(4):626\u2013631","journal-title":"Cancer Sci"},{"issue":"6","key":"7_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ (2003) Timeline: the pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat Rev Cancer 3(6):453\u2013458","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"7_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/107327481201900203","volume":"19","author":"RL Theriault","year":"2012","unstructured":"Theriault RL, Theriault RL (2012) Biology of bone metastases. Cancer Control 19(2):92\u2013101","journal-title":"Cancer Control"},{"issue":"1","key":"7_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/fon.09.138","volume":"6","author":"AA Rose","year":"2010","unstructured":"Rose AA, Siegel PM (2010) Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6(1):55\u201374","journal-title":"Future Oncol"},{"issue":"7084","key":"7_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature04524","volume":"440","author":"DH Jones","year":"2006","unstructured":"Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong Y-Y, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692\u2013696","journal-title":"Nature"},{"issue":"6824","key":"7_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Ver\u00e1stegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50\u201356","journal-title":"Nature"},{"issue":"2","key":"7_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10(2):169\u2013180","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2 Suppl 6","key":"7_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0093-7754(01)90260-X","volume":"28","author":"RE Coleman","year":"2001","unstructured":"Coleman RE, Seaman JJ (2001) The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 28(2 Suppl 6):11\u201316","journal-title":"Semin Oncol"},{"issue":"2","key":"7_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","volume":"10","author":"JM Chirgwin","year":"2000","unstructured":"Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159\u2013178","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"26","key":"7_CR26","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1056\/NEJMra0805239","volume":"359","author":"AC Chiang","year":"2008","unstructured":"Chiang AC, Massagu\u00e9 J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814\u20132823","journal-title":"N Engl J Med"},{"issue":"11","key":"7_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrclinonc.2010.134","volume":"7","author":"T Onishi","year":"2010","unstructured":"Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641\u2013651","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"7_CR28","first-page":"570","volume":"2","author":"TA Guise","year":"2002","unstructured":"Guise TA (2002) The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2(6):570\u2013572","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"16","key":"7_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655\u20131664","journal-title":"N Engl J Med"},{"issue":"2","key":"7_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L\u00fcthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309\u2013319","journal-title":"Cell"},{"issue":"3","key":"7_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1677\/erc.1.00543","volume":"12","author":"GA Clines","year":"2005","unstructured":"Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549\u2013583","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"7_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers H (2006) Wnt\/\u03b2-catenin signaling in development and disease. Cell 127(3):469\u2013480","journal-title":"Cell"},{"issue":"7","key":"7_CR33","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","volume":"97","author":"N Voorzanger-Rousselot","year":"2007","unstructured":"Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Cl\u00e9zardin P, Garnero P (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97(7):964\u2013970","journal-title":"Br J Cancer"},{"issue":"26","key":"7_CR34","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483\u20132494","journal-title":"N Engl J Med"},{"issue":"2","key":"7_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/bcr2835","volume":"13","author":"P Cl\u00e9zardin","year":"2011","unstructured":"Cl\u00e9zardin P (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 13(2):207","journal-title":"Breast Cancer Res"},{"issue":"7","key":"7_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1471-4914(02)02340-7","volume":"8","author":"X Yang","year":"2002","unstructured":"Yang X, Karsenty G (2002) Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 8(7):340\u2013345","journal-title":"Trends Mol Med"},{"issue":"3","key":"7_CR37","first-page":"917","volume":"62","author":"B Yi","year":"2002","unstructured":"Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62(3):917\u2013923","journal-title":"Cancer Res"},{"issue":"5","key":"7_CR38","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/en.2005-1502","volume":"147","author":"MP Valta","year":"2006","unstructured":"Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Sepp\u00e4nen JA, V\u00e4\u00e4n\u00e4nen HK, H\u00e4rk\u00f6nen PL (2006) Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology 147(5):2171\u20132182","journal-title":"Endocrinology"},{"issue":"9","key":"7_CR39","doi-asserted-by":"publisher","first-page":"e6896","DOI":"10.1371\/journal.pone.0006896","volume":"4","author":"LK Dunn","year":"2009","unstructured":"Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA (2009) Hypoxia and TGF-\u03b2 drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 4(9):e6896","journal-title":"PLoS One"},{"issue":"18","key":"7_CR40","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","volume":"65","author":"J Dai","year":"2005","unstructured":"Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET (2005) Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65(18):8274\u20138285","journal-title":"Cancer Res"},{"issue":"S3","key":"7_CR41","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/cncr.11129","volume":"97","author":"TA Guise","year":"2003","unstructured":"Guise TA, Yin JJ, Mohammad KS (2003) Role of endothelin-1 in osteoblastic bone metastases. Cancer 97(S3):779\u2013784","journal-title":"Cancer"},{"issue":"2","key":"7_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1210\/me.2006-0346","volume":"21","author":"GA Clines","year":"2007","unstructured":"Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21(2):486\u2013498","journal-title":"Mol Endocrinol"},{"issue":"19","key":"7_CR43","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.1830978100","volume":"100","author":"JJ Yin","year":"2003","unstructured":"Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci 100(19):10954\u201310959","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"7_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/cncr.21305","volume":"104","author":"EO Hanrahan","year":"2005","unstructured":"Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau S-WC, Hortobagyi GN, Rivera E (2005) Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 104(6):1158\u20131171","journal-title":"Cancer"},{"issue":"1","key":"7_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0022-5223(97)70121-1","volume":"114","author":"M Incarbone","year":"1997","unstructured":"Incarbone M, Nava M, Lequaglie C, Ravasi G, Pastorino U (1997) Sternal resection for primary or secondary tumors. J Thorac Cardiovasc Surg 114(1):93\u201399","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7_CR46","doi-asserted-by":"crossref","unstructured":"D\u00fcrr HR, M\u00fcller PE, Lenz T, Baur A, Jansson V, Refior HJ (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191\u2013196","DOI":"10.1097\/00003086-200203000-00029"},{"issue":"5","key":"7_CR47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3928\/0147-7447-19920501-05","volume":"15","author":"RC Thompson","year":"1992","unstructured":"Thompson RC (1992) Impending fracture associated with bone destruction. Orthopedics 15(5):547\u2013550","journal-title":"Orthopedics"},{"issue":"8 Suppl","key":"7_CR48","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1614::AID-CNCR12>3.0.CO;2-2","volume":"80","author":"KD Harrington","year":"1997","unstructured":"Harrington KD (1997) Orthopedic surgical management of skeletal complications of malignancy. Cancer 80(8 Suppl):1614\u20131627","journal-title":"Cancer"},{"issue":"5","key":"7_CR49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","volume":"50","author":"D Tong","year":"1982","unstructured":"Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50(5):893\u2013899","journal-title":"Cancer"},{"issue":"4","key":"7_CR50","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0360-3016(95)00572-G","volume":"32","author":"E Maranzano","year":"1995","unstructured":"Maranzano E, Latini P (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32(4):959\u2013967","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"7_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00000421-199008000-00005","volume":"13","author":"JE Perez","year":"1990","unstructured":"Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA, Alvarez LA (1990) Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncol\u00f3gico Cooperativo del Sur. Am J Clin Oncol 13(4):294\u2013298","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"7_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","volume":"161","author":"BA Leone","year":"2017","unstructured":"Leone BA, Vallejo CT, Romero AO, Machiavelli MR, P\u00e9rez JE, Leone J, Leone JP (2017) Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat 161(3):537\u2013548","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4143\/crt.2011.43.2.89","volume":"43","author":"SJ Lee","year":"2011","unstructured":"Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang J-H, Park YH, Ahn JS, Im Y-H (2011) Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat 43(2):89\u201395","journal-title":"Cancer Res Treat"},{"issue":"2","key":"7_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1634\/theoncologist.2010-0350","volume":"16","author":"N Niikura","year":"2011","unstructured":"Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL (2011) Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist 16(2):155\u2013164","journal-title":"Oncologist"},{"issue":"11","key":"7_CR55","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00520-007-0244-9","volume":"15","author":"IJ Diel","year":"2007","unstructured":"Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15(11):1243\u20131249","journal-title":"Support Care Cancer"},{"key":"7_CR56","first-page":"CD003474","volume-title":"Cochrane database of systematic reviews, no. 2","author":"MH Wong","year":"2012","unstructured":"Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. In: Pavlakis N (ed) Cochrane database of systematic reviews, no. 2. Wiley, Chichester, p CD003474"},{"issue":"Suppl 1","key":"7_CR57","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.3747\/co.2008.176","volume":"15","author":"B Petrut","year":"2008","unstructured":"Petrut B, Trinkaus M, Simmons C, Clemons M (2008) A primer of bone metastases management in breast cancer patients. Curr Oncol 15(Suppl 1):S50\u2013S57","journal-title":"Curr Oncol"},{"issue":"8","key":"7_CR58","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28(8):1729\u20131737","journal-title":"J Bone Miner Res"},{"issue":"28","key":"7_CR59","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body J-J, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AHG, Peterson MC, Fan M, Kinsey A, Jun S (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25(28):4431\u20134437","journal-title":"J Clin Oncol"},{"issue":"2","key":"7_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119\u2013129","journal-title":"Clin Exp Metastasis"},{"issue":"35","key":"7_CR61","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132\u20135139","journal-title":"J Clin Oncol"},{"issue":"9768","key":"7_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822","journal-title":"Lancet"},{"issue":"9","key":"7_CR63","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125\u20131132","journal-title":"J Clin Oncol"},{"issue":"16","key":"7_CR64","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092","journal-title":"Eur J Cancer"},{"issue":"3","key":"7_CR65","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22(3):679\u2013687","journal-title":"Support Care Cancer"},{"issue":"6","key":"7_CR66","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/ol.2014.1982","volume":"7","author":"X Wang","year":"2014","unstructured":"Wang X, Yang KH, Wanyan P, Tian JH (2014) Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett 7(6):1997\u20132002","journal-title":"Oncol Lett"},{"issue":"34","key":"7_CR67","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580\u20138587","journal-title":"J Clin Oncol"},{"issue":"5","key":"7_CR68","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23(5):1341\u20131347","journal-title":"Ann Oncol"},{"issue":"7","key":"7_CR69","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663\u2013670","journal-title":"Lancet Oncol"},{"issue":"7","key":"7_CR70","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"Gabriel N. Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3(7):906\u2013912","journal-title":"JAMA Oncology"},{"issue":"1","key":"7_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. JAMA 317(1):48","journal-title":"JAMA"},{"issue":"6","key":"7_CR72","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","volume":"6","author":"IG Finlay","year":"2005","unstructured":"Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6(6):392\u2013400","journal-title":"Lancet Oncol"},{"issue":"14","key":"7_CR73","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942\u20132953","journal-title":"J Clin Oncol"},{"issue":"2","key":"7_CR74","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","volume":"22","author":"J Rong","year":"2013","unstructured":"Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S (2013) Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 22(2):86\u201391","journal-title":"Surg Oncol"},{"issue":"9","key":"7_CR75","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/bjc.2015.112","volume":"112","author":"OA Catalano","year":"2015","unstructured":"Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, Guimaraes A, Vangel MG, Mahmood U, Soricelli A, Salvatore M (2015) Comparison of CE-FDG-PET\/CT with CE-FDG-PET\/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer 112(9):1452\u20131460","journal-title":"Br J Cancer"},{"issue":"2","key":"7_CR76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.6004\/jnccn.2011.0016","volume":"9","author":"RW Carlson","year":"2011","unstructured":"Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung B-M, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Lou Smith M, Somlo G, Ward JH, Wolff AC, Zellars R, National Comprehensive Cancer Network (2011) Invasive breast cancer. J Natl Compr Cancer Netw 9(2):136\u2013222","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"7_CR77","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.bjc.6605546","volume":"102","author":"T Hamaoka","year":"2010","unstructured":"Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT (2010) Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102(4):651\u2013657","journal-title":"Br J Cancer"},{"issue":"8","key":"7_CR78","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2967\/jnumed.110.076455","volume":"51","author":"U Giorgi De","year":"2010","unstructured":"De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT (2010) 18F-FDG PET\/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51(8):1213\u20131218","journal-title":"J Nucl Med"},{"issue":"Suppl_1","key":"7_CR79","doi-asserted-by":"publisher","first-page":"34S","DOI":"10.2967\/jnumed.115.157875","volume":"57","author":"S Avril","year":"2016","unstructured":"Avril S, Muzic RF, Plecha D, Traughber BJ, Vinayak S, Avril N (2016) 18F-FDG PET\/CT for monitoring of treatment response in breast cancer. J Nucl Med 57(Suppl_1):34S\u201339S","journal-title":"J Nucl Med"},{"issue":"9","key":"7_CR80","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","volume":"44","author":"Christopher C. Riedl","year":"2017","unstructured":"Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, G\u00f6nen M, Dickler M, Weber WA (2017) Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 44(9):1428\u20131437","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"7_CR81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","volume":"1","author":"CM Costelloe","year":"2010","unstructured":"Costelloe CM, Chuang HH, Madewell JE, Ueno NT (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80\u201392","journal-title":"J Cancer"},{"issue":"8","key":"7_CR82","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1200\/JCO.2000.18.8.1676","volume":"18","author":"IC Smith","year":"2000","unstructured":"Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF (2000) Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18(8):1676\u20131688","journal-title":"J Clin Oncol"},{"issue":"3","key":"7_CR83","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00000658-200103000-00002","volume":"233","author":"BL Br\u00fccher","year":"2001","unstructured":"Br\u00fccher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233(3):300\u2013309","journal-title":"Ann Surg"},{"issue":"7","key":"7_CR84","first-page":"1144","volume":"46","author":"J Dose Schwarz","year":"2005","unstructured":"Dose Schwarz J, Bader M, Jenicke L, Hemminger G, J\u00e4nicke F, Avril N (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46(7):1144\u20131150","journal-title":"J Nucl Med"},{"issue":"19","key":"7_CR85","doi-asserted-by":"publisher","first-page":"27848","DOI":"10.18632\/oncotarget.8425","volume":"7","author":"SJ Min","year":"2016","unstructured":"Min SJ, Jang HJ, Kim JH (2016) Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget 7(19):27848\u201327854","journal-title":"Oncotarget"},{"issue":"5","key":"7_CR86","first-page":"295","volume":"2","author":"GA Clines","year":"2004","unstructured":"Clines GA, Guise TA (2004) Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2(5):295\u2013302","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"7_CR87","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1185\/030079902125000543","volume":"18","author":"LM Pickering","year":"2002","unstructured":"Pickering LM, Mansi JL (2002) The role of bisphosphonates in breast cancer management: review article. Curr Med Res Opin 18(5):284\u2013295","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"7_CR88","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWMM, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781\u2013791","journal-title":"N Engl J Med"},{"issue":"7","key":"7_CR89","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420\u20131430","journal-title":"J Clin Oncol"},{"issue":"8","key":"7_CR90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMoa050434","volume":"353","author":"S Braun","year":"2005","unstructured":"Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga J-Y, Marth C, Oruzio D, Wiedswang G, Solomayer E-F, Kundt G, Strobl B, Fehm T, Wong GYC, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793\u2013802","journal-title":"N Engl J Med"},{"issue":"3","key":"7_CR91","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-015-3636-4","volume":"154","author":"Z Mu","year":"2015","unstructured":"Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M (2015) Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat 154(3):563\u2013571","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"7_CR92","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","volume":"12","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LWWM (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14):4218\u20134224","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/annonc\/mdp262","volume":"21","author":"U Giorgi De","year":"2010","unstructured":"De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M (2010) Circulating tumor cells and bone metastases as detected by FDG-PET\/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33\u201339","journal-title":"Ann Oncol"},{"issue":"4","key":"7_CR94","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"F-C Bidard","year":"2014","unstructured":"Bidard F-C, Peeters DJ, Fehm T, Nol\u00e9 F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri M-T, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson S-J, Raimondi C, Rutten A, Janni W, Munzone E, Cara\u00f1ana V, Agelaki S, Almici C, Dirix L, Solomayer E-F, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga J-Y, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406\u2013414","journal-title":"Lancet Oncol"},{"issue":"1","key":"7_CR95","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12282-014-0539-x","volume":"23","author":"Y Shiomi-Mouri","year":"2016","unstructured":"Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, Fujii K, Akizuki M, Imai T, Fukutomi T, Kobayashi K (2016) Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced\/metastatic breast cancer. Breast Cancer 23(1):120\u2013127","journal-title":"Breast Cancer"},{"issue":"1","key":"7_CR96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13058-016-0687-3","volume":"18","author":"M Bulfoni","year":"2016","unstructured":"Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D (2016) In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res 18(1):30","journal-title":"Breast Cancer Res"},{"key":"7_CR97","doi-asserted-by":"publisher","first-page":"43464","DOI":"10.1038\/srep43464","volume":"7","author":"W-T Yan","year":"2017","unstructured":"Yan W-T, Cui X, Chen Q, Li Y-F, Cui Y-H, Wang Y, Jiang J (2017) Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep 7:43464","journal-title":"Sci Rep"},{"issue":"3","key":"7_CR98","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/annonc\/mdr263","volume":"23","author":"J-Y Pierga","year":"2012","unstructured":"Pierga J-Y, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C, Bidard F-C (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23(3):618\u2013624","journal-title":"Ann Oncol"},{"issue":"7","key":"7_CR99","doi-asserted-by":"publisher","first-page":"e1600274","DOI":"10.1126\/sciadv.1600274","volume":"2","author":"BL Khoo","year":"2016","unstructured":"Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT (2016) Liquid biopsy and therapeutic response: circulating tumor cell cultures for evaluation of anticancer treatment. Sci Adv 2(7):e1600274","journal-title":"Sci Adv"},{"issue":"4","key":"7_CR100","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.3390\/cancers3022106","volume":"3","author":"KM Britton","year":"2011","unstructured":"Britton KM, Kirby JA, Lennard TWJ, Meeson AP (2011) Cancer stem cells and side population cells in breast cancer and metastasis. Cancer (Basel) 3(4):2106\u20132130","journal-title":"Cancer (Basel)"},{"issue":"11","key":"7_CR101","doi-asserted-by":"publisher","first-page":"e14131","DOI":"10.1371\/journal.pone.0014131","volume":"5","author":"C Marchini","year":"2010","unstructured":"Marchini C, Montani M, Konstantinidou G, Orr\u00f9 R, Mannucci S, Ramadori G, Gabrielli F, Baruzzi A, Berton G, Merigo F, Fin S, Iezzi M, Bisaro B, Sbarbati A, Zerani M, Gali\u00e8 M, Amici A (2010) Mesenchymal\/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 5(11):e14131","journal-title":"PLoS One"},{"issue":"2","key":"7_CR102","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","volume":"36","author":"F Saad","year":"2010","unstructured":"Saad F, Lipton A (2010) SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36(2):177\u2013184","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"7_CR103","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1600-0463.2011.02864.x","volume":"120","author":"L Zhang","year":"2012","unstructured":"Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y, Qu X (2012) c-Src expression is predictive of poor prognosis in breast cancer patients with bone metastasis, but not in patients with visceral metastasis. APMIS 120(7):549\u2013557","journal-title":"APMIS"},{"issue":"1","key":"7_CR104","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/jpet.106.102004","volume":"318","author":"N Rucci","year":"2006","unstructured":"Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A (2006) Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 318(1):161\u2013172","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"7_CR105","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-11-0070","volume":"17","author":"EL Mayer","year":"2011","unstructured":"Mayer EL, Baurain J-F, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A (2011) A phase 2 trial of dasatinib in patients with advanced HER2-positive and\/or hormone receptor-positive breast cancer. Clin Cancer Res 17(21):6897\u20136904","journal-title":"Clin Cancer Res"},{"issue":"18","key":"7_CR106","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-11-1071","volume":"17","author":"CI Herold","year":"2011","unstructured":"Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL (2011) Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 17(18):6061\u20136070","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7_CR107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-016-3911-z","volume":"159","author":"AF Schott","year":"2016","unstructured":"Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159(1):87\u201395","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"7_CR108","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1093\/annonc\/mdr018","volume":"22","author":"MN Fornier","year":"2011","unstructured":"Fornier MN, Morris PG, Abbruzzi A, D\u2019Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA (2011) A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 22(12):2575\u20132581","journal-title":"Ann Oncol"},{"issue":"7","key":"7_CR109","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-12-0652","volume":"19","author":"G Somlo","year":"2013","unstructured":"Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J (2013) Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res 19(7):1884\u20131893","journal-title":"Clin Cancer Res"},{"key":"7_CR110","doi-asserted-by":"crossref","first-page":"73144","DOI":"10.18632\/oncotarget.17113","volume":"8","author":"A Ocana","year":"2015","unstructured":"Ocana A, Gil-Martin M, Mart\u00edn M, Rojo F, Antol\u00edn S, Guerrero \u00c1, Trigo JM, Mu\u00f1oz M, Carrasco E, Urruticoechea A, Bezares S, Caballero R, Carrasco E, Urruticoechea A (2015) A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM\/2010-04 study. Oncotarget 8:73144\u201373153","journal-title":"Oncotarget"},{"issue":"23","key":"7_CR111","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/1078-0432.CCR-15-2845","volume":"22","author":"Z Mitri","year":"2016","unstructured":"Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S, Translational Breast Cancer Research Consortium (2016) TBCRC-010: phase I\/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis. Clin Cancer Res 22(23):5706\u20135712","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7_CR112","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4161\/cbt.4.3.1566","volume":"4","author":"S Iyer","year":"2005","unstructured":"Iyer S, Wang Z-G, Akhtari M, Zhao W, Seth P (2005) Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 4(3):261\u2013266","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"7_CR113","first-page":"381","volume":"143","author":"BI Dalal","year":"1993","unstructured":"Dalal BI, Keown PA, Greenberg AH (1993) Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143(2):381\u2013389","journal-title":"Am J Pathol"},{"issue":"2","key":"7_CR114","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1158\/1078-0432.CCR-0320-03","volume":"10","author":"MB Buck","year":"2004","unstructured":"Buck MB, Fritz P, Dippon J, Zugmaier G, Knabbe C (2004) Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 10(2):491\u2013498","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7_CR115","first-page":"2099","volume":"29","author":"MP Rausch","year":"2009","unstructured":"Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung H-K, Lee W-C, Ling LE, Akporiaye ET (2009) An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Res 29(6):2099\u20132109","journal-title":"Anticancer Res"},{"issue":"4","key":"7_CR116","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00262-011-1119-y","volume":"61","author":"K Garrison","year":"2012","unstructured":"Garrison K, Hahn T, Lee W-C, Ling LE, Weinberg AD, Akporiaye ET (2012) The small molecule TGF-\u03b2 signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 61(4):511\u2013521","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"7_CR117","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1476-4598-9-122","volume":"9","author":"V Ganapathy","year":"2010","unstructured":"Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M (2010) Targeting the transforming growth factor-\u03b2 pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9(1):122","journal-title":"Mol Cancer"},{"issue":"1","key":"7_CR118","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djs485","volume":"105","author":"Y Fang","year":"2013","unstructured":"Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Shi T, Luo J, Liu M (2013) Inhibition of breast cancer metastases by a novel inhibitor of TGF receptor 1. J Natl Cancer Inst 105(1):47\u201358","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"7_CR119","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagu\u00e9 J, Mundy GR, Guise TA (1999) TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103(2):197\u2013206","journal-title":"J Clin Invest"},{"issue":"3","key":"7_CR120","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/np300663v","volume":"76","author":"LE Wright","year":"2013","unstructured":"Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL (2013) Curcuminoids block TGF-\u03b2 signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod 76(3):316\u2013321","journal-title":"J Nat Prod"},{"key":"7_CR121","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pharmthera.2014.11.001","volume":"147","author":"C Neuzillet","year":"2015","unstructured":"Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A (2015) Targeting the TGF\u03b2 pathway for cancer therapy. Pharmacol Ther 147:22\u201331","journal-title":"Pharmacol Ther"},{"issue":"6","key":"7_CR122","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/annonc\/mdn740","volume":"20","author":"N Cabioglu","year":"2009","unstructured":"Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013\u20131019","journal-title":"Ann Oncol"},{"issue":"3","key":"7_CR123","first-page":"761","volume":"21","author":"MM Richert","year":"2009","unstructured":"Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21(3):761\u2013767","journal-title":"Oncol Rep"},{"issue":"24","key":"7_CR124","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1158\/1078-0432.CCR-07-4846","volume":"14","author":"D Wong","year":"2008","unstructured":"Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14(24):7975\u20137980","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7_CR125","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jss.2008.06.044","volume":"155","author":"EH Huang","year":"2009","unstructured":"Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231\u2013236","journal-title":"J Surg Res"},{"issue":"1","key":"7_CR126","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ijc.25665","volume":"129","author":"S Hassan","year":"2011","unstructured":"Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129(1):225\u2013232","journal-title":"Int J Cancer"},{"issue":"1","key":"7_CR127","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1476-4598-9-250","volume":"9","author":"SA Williams","year":"2010","unstructured":"Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR (2010) Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 9(1):250","journal-title":"Mol Cancer"},{"issue":"14","key":"7_CR128","doi-asserted-by":"publisher","first-page":"E1291","DOI":"10.1073\/pnas.1220580110","volume":"110","author":"M Gil","year":"2013","unstructured":"Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D (2013) Targeting CXCL12\/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci 110(14):E1291\u2013E1300","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"7_CR129","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","volume":"14","author":"S-B Peng","year":"2015","unstructured":"Peng S-B, Zhang X, Paul D, Kays LM, Gough W, Stewart J, Uhlik MT, Chen Q, Hui Y-H, Zamek-Gliszczynski MJ, Wijsman JA, Credille KM, Yan LZ (2015) Targeting CXCL12\/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Mol Cancer Ther 14(2):480\u2013490","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"7_CR130","first-page":"252","volume":"44","author":"G Henriksen","year":"2003","unstructured":"Henriksen G, Fisher DR, Roeske JC, Bruland \u00d8S, Larsen RH (2003) Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 44(2):252\u2013259","journal-title":"J Nucl Med"},{"issue":"7","key":"7_CR131","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern\u00e4s B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8(7):587\u2013594","journal-title":"Lancet Oncol"},{"issue":"3","key":"7_CR132","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franz\u00e9n L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland \u00d8S, Sartor O, ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"2","key":"7_CR133","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","volume":"145","author":"R Coleman","year":"2014","unstructured":"Coleman R, Aksnes A-K, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 145(2):411\u2013418","journal-title":"Breast Cancer Res Treat"}],"container-title":["Advances in Experimental Medicine and Biology","Breast Cancer Metastasis and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-20301-6_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T14:44:10Z","timestamp":1664203450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-20301-6_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030203009","9783030203016"],"references-count":133,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-20301-6_7","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"28 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}